CNRS, Institute of Developmental Biology and Cancer Research Université de Nice, France.
J Immunother. 2012 Feb-Mar;35(2):154-8. doi: 10.1097/CJI.0b013e318243f238.
There is now substantial evidence that imatinib may affect immune responses, especially those mediated by T lymphocytes. Fas (CD95/Apo-1), a cell death receptor, is a key regulator of the immune system. We have explored the consequences of treatment on the Fas system in chronic myeloid leukemia patients treated with imatinib. In comparison with healthy controls, we found not only a mild blood lymphopenia but also impairment of phytohemagglutinin activation in CD4Fas and CD8Fas lymphocytes of imatinib-treated patients. Moreover, these lymphocyte populations were more sensitive to FasL-induced cell death in relation to an increase in Fas expression at the cell surface. Taken together, these results reveal the role of Fas receptor in the lymphopenia observed in patients treated with imatinib, with potential deleterious consequences on antileukemic responses against this immunogenic hematological malignancy.
现在有大量证据表明伊马替尼可能会影响免疫反应，尤其是 T 淋巴细胞介导的免疫反应。Fas（CD95/Apo-1）是一种细胞死亡受体，是免疫系统的关键调节因子。我们已经探讨了伊马替尼治疗对慢性髓性白血病患者 Fas 系统的影响。与健康对照组相比，我们不仅发现轻度的血液淋巴细胞减少，而且还发现伊马替尼治疗患者的 CD4Fas 和 CD8Fas 淋巴细胞对植物血凝素激活的反应受损。此外，这些淋巴细胞群体对 FasL 诱导的细胞死亡更加敏感，这与细胞表面 Fas 表达的增加有关。总之，这些结果揭示了 Fas 受体在接受伊马替尼治疗的患者中观察到的淋巴细胞减少中的作用，这可能对针对这种免疫原性血液恶性肿瘤的抗白血病反应产生有害影响。
